Phase I, multi-centre, randomised, placebo-controlled, dose escalation study to assess local and systemic tolerability of therapeutic DNA plasmid pdpSC18 vaccine administered by Particle Mediated Epidermal Delivery using PowderJect ND10 delivery system in subjects with chronic hepatitis B infection
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2008
At a glance
- Drugs Hepatitis B DNA vaccine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 20 Nov 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 20 Nov 2008 Actual trial completion date identified as December 2007 from ClinicalTrials.gov.
- 04 Apr 2006 New trial record.